Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Depreciation & Amortization (CF) (2016 - 2025)

Cytokinetics (CYTK) has disclosed Depreciation & Amortization (CF) for 16 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) changed N/A to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.3 million, a N/A change, with the full-year FY2025 number at $10.1 million, up 6.23% from a year prior.
  • Depreciation & Amortization (CF) was $3.0 million for Q4 2025 at Cytokinetics, up from $2.3 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $6.3 million in Q4 2023 to a low of $462000.0 in Q3 2021.
  • A 5-year average of $1.9 million and a median of $1.8 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): fell 13.81% in 2021, then surged 282.09% in 2023.
  • Cytokinetics' Depreciation & Amortization (CF) stood at $734000.0 in 2021, then surged by 125.89% to $1.7 million in 2022, then soared by 282.09% to $6.3 million in 2023, then plummeted by 61.94% to $2.4 million in 2024, then increased by 23.48% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Depreciation & Amortization (CF) are $3.0 million (Q4 2025), $2.3 million (Q1 2025), and $2.4 million (Q3 2024).